Early intervention of skin toxicities by panitumumab and clinical outcomes in the clinical setting.

e20673 Background: Dermatologic toxicities from panitumumab can interfere with consistent cancer treatment. While treatment algorithms have been proposed for managing dermatologic toxicities, they are only stringently followed within a clinical trial setting. We assessed the impact of early versus late intervention of rash by initial grade in a cohort of patients treated outside of a clinical trial setting. Methods: We evaluated retrospectively the assessment and management of skin toxicities related to panitumumab in a consecutive cohort of patients receiving panitumumab for the treatment of metastatic colorectal cancer outside of a clinical trial from April 2009-August 2012. Results: Of 34 patients, 32 (94%) had a reported panitumumab-related skin toxicity (papulopustular rash). 85% developed the rash by the end of the second infusion cycle. A severity grading system was reported for 65% of patients: 31% used the CTCAE grading system, while 34% used mild/moderate/severe terminology; the remaining 34%, g...